|
[1]DANDRI M,PETERSEN J.Latest developments in the treatment of hepatitis B[J].Minerva Gastroenterol Dietol,2016,62(1):88-102.
|
|
[2]NI Y,LEMPP FA,MEHRLE S,et al.Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J].Gastroenterology,2014,146(4):1070-1083.
|
|
[3]YAN H,ZHONG G,XU G,et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].ELife,2012,1:e00049.
|
|
[4]PETERSEN J,DANDRI M,MIER W,et al.Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein[J].Nat Biotechnol,2008,26(3):335-341.
|
|
[5]VOLZ T,ALLWEISS L,BEN MBAREK M,et al.The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus[J].J Hepatol,2013,58(5):861-867.
|
|
[6]BOGOMOLOV P,VORONKOVA N,ALLWEISS L,et al.A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B[J].Hepatology,2014,60:1279a-1280a.
|
|
[7]KONIGER C,WINGERT I,MARSMANN M,et al.Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses[J].Proc Natl Acad Sci U S A,2014,111(40):e4244-e4253.
|
|
[8]CUI X,McA LLISTER R,BOREGOWDA R,et al.Does tyrosyl DNA phosphodiesterase-2 play a role in hepatitis B virus genome repair?[J].PLoS One,2015,10(6):e0128401.
|
|
[9]KENNEDY EM,BASSIT LC,MUELLER H,et al.Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease[J].Virology,2015,476(2):196-205.10]RAMANAN V,SHLOMAI A,COX DB,et al.CRISPR/Cas9cleavage of viral DNA efficiently suppresses hepatitis B virus[J].Sci Rep,2015,5(6):10833.11]ZHEN S,HUA L,LIU YH,et al.Harnessing the clustered regularly interspaced short palindromic repeat(CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus[J].Gene Ther,2015,22(5):404-412.
|
|
[12]CAI D,MILLS C,YU W,et al.Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation[J].Antimicrob Agents Chemother,2012,56(8):4277-4288.
|
|
[13] GUO H,JIANG D,ZHOU T,et al.Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus:an intermediate of covalently closed circular DNA formation[J].J Virol,2007,81(22):12472-12484.
|
|
[14]LUCIFORA J,XIA Y,REISIGNER F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus ccc DNA[J].Science,2014,343(6176):1221-1228.
|
|
[15]ZLOTNICK A,VENKATAKRISHNAN B,TAN Z,et al.Core protein:a pleiotropic keystone in the HBV lifecycle[J].Antiviral Res,2015,121(9):82-93.
|
|
[16]BELLOIN L,PALUMBO GA,LUPACCHINI L,et al.Capsid drugs HAP12 and AT130 target HBV core protein nuclear functions[J].J Hepatol,2015,62(Suppl 2):s513-s514.
|
|
[17]DERES K,SCHRDER CH,PAESSENS A,et al.Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids[J].Science,2003,299(5608):893-896.
|
|
[18]STRAY SJ,BOURNE CR,PUNNA S,et al.A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly[J].Proc Natl Acad Sci U S A,2005,102(23):8138-8143.
|
|
[19]KLUMPP K,SHIMADA T,ALLWEISS L,et al.High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized UPA/SCID mouse model[J].J Hepatol,2015,62(Suppl 2):s250.
|
|
[20]LAM A,ESPIRITU C,FLORES O,et al.Effect of the combination of the HBV core inhibitor NVR 3-778 with nucleoside analogs or other HBV core inhibitors on the inhibition of HBV DNA replication in HepG 2.2.15 cells[J].J Hepatol,2015,62(Suppl 2):s559.
|
|
[21]GANE EJ,SCHWABE C,WALKER K,et al.Phase 1a safety and pharmacokinetics of NVR 3-778,a potential first-in-class HBV core inhibitor[J].Hepatology,2014,60(6):1279a.
|
|
[22]KLUMPP K,LAM AM,LUKACS C,et al.High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein[J].Proc Natl Acad Sci U S A,2015,112(49):15196-15201.
|
|
[23]BLOCK TM,LU X,PLATT FM,et al.Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin[J].Proc Natl Acad Sci U S A,1994,91(6):2235-2239.
|
|
[24]DURANTEL D,ALOTTE C,ZOULIM F.Glucosidase inhibitors as antiviral agents for hepatitis B and C[J].Curr Opin Investig Drugs,2007,8(2):125-129.
|
|
[25]YU W,GODDARD C,CLEARFIELD E,et al.Design,synthesis,and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen(HBsA g)secretion[J].J Med Chem,2011,54(16):5660-5670.
|
|
[26]XU YB,YANG L,WANG GF,et al.Benzimidazole derivative,BM601,a novel inhibitor of hepatitis B virus and HBs Ag secretion[J].Antiviral Res,2014,107(7):6-15.
|
|
[27]NORDEEN F,GROSSE A,JUTEAU JM,et al.Therapeutic efficacy of the amphipathic DNA polymer REP 9AC in the treatment of duck hepatitis B virus infection in vivo[J].Antiviral Res,2009,82(2):a30-a31.
|
|
[28]MAHTAB M,BAZINET M,VAILLANT A,et al.Establishment of a potent anti-HBsA g response and durable immunological control of viremia with short term immunotherapy after REP 9ACinduced HBsA g seroclearance in chronic HBV infection[J].J Hepatol,2013,58(Suppl 1):s316.
|
|
[29]Mc CAFFREY AP,NAKAI H,PANDEY K,et al.Inhibition of hepatitis B virus in mice by RNA interference[J].Nat Biotechnol,2003,21(6):639-644.
|
|
[30]SHLOMAI A,SHAUL Y.Inhibition of hepatitis B virus expression and replication by RNA interference[J].Hepatology,2003,37(4):764-770.
|
|
[31]SHLOMAI A,SHAUL Y.RNA interference-smal RNAs effectively fight viral hepatitis[J].Liver Int,2004,24(6):526-531.
|
|
[32]YUEN MF,CHAN HL,GIVEN B,et al.Phase II,dose ranging study of ARC-520,a siRNA-based therapeutic,in patients with chronic hepatitis B virus infection[J].Hepatology,2014,60(6):1280a.
|
|
[33]SEBESTYN MG,WONG SC,TRUBESKOY V,et al.Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes[J].Methods Mol Biol,2015,1218:163-186.
|
|
[34]MACLACHLAN I.Update on the preclinical development of an LNP-based HBV therapeutic[C].10th Annual Meeting of the Oligonucleotide Therapeutics Society.San Diego,California,USA,2014.
|
|
[35]PHILLIPS S,CHOKSHI S,CHATTERJI U,et al.Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production[J].Gastroenterology,2015,148(2):403-414.
|
|
[36]NILLON J,MOSS S,COATES N,et al.NVP018,a cyclophilin inhibitor for treatment of chronic HBV infection[J].J Hepatol,2014,60(Suppl 1):s423.
|
|
[37]JIANG M,BROERING R,TRIPPLER M,et al.Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J].J Viral Hepat,2014,21(12):860-872.
|
|
[38]ZHANG X,MA Z,LIU H,et al.Role of Toll-like receptor 2in the immune response against hepadnaviral infection[J].J Hepatol,2012,57(3):522-528.
|
|
[39]WU J,MENG Z,JIANG M,et al.Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells[J].Hepatology,2009,49(4):1132-1140.
|
|
[40]WU J,LU M,MENG Z,et al.Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice[J].Hepatology,2007,46(6):1769-1778.
|
|
[41]THOMPSON AJ,COLLEDGE D,RODGERS S,et al.Stimulation of the interleukin-1 receptor and Toll-like receptor 2inhibits hepatitis B virus replication in hepatoma cell lines in vitro[J].Antivir Ther,2009,14(6):797-808.
|
|
[42]GILES M,VISVANATHAN K,LEWIN S,et al.Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B[J].Gut,2015,64(11):1810-1815.
|
|
[43]VISVANATHAN K,SKINNER NA,THOMPSON AJ,et al.Regulation of Toll-like receptor-2 expression in chronic hepatitis By the precore protein[J].Hepatology,2007,45(1):102-110.
|
|
[44]LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.
|
|
[45]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,63(2):320-328.
|
|
[46]REBBAPRAGADA I,BIRKUS G,PERRY J,et al.Molecular determinants of GS-9620-dependent TLR7 activation[J].PLoS One,2016,11(1):e0146835.
|
|
[47] LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517.
|
|
[48]MENNE S,TUMAS DB,LIU KH,et al.Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620in the Woodchuck model of chronic hepatitis B[J].J Hepatol,2015,62(6):1237-1245.
|
|
[49]SATO S,LI K,KAMEYAMA T,et al.The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus[J].Immunity,2015,42(1):123-132.
|
|
[50]KOROLOWICZ K,CZERWINSKI S,IYER R,et al.Antiviral efficacy and induction of host immune responses with SB9200,an oral prodrug of the dinucleotide SB 9000,in the woodchuck model of chronic hepatitis B virus(HBV)infection[J].J Hepatol,2015,62(Suppl 2):s557.
|
|
[51]CHEN L,FLIES DB.Molecular mechanisms of T cell costimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
|
|
[52]RAZIORROUH B,SCHRAUT W,GERLACH T,et al.The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+Tcell function[J].Hepatology,2010,52(6):1934-1947.
|
|
[53] BLACKBURN SD,SHIN H,HAINING WN,et al.Coregulation of CD8+T cell exhaustion by multiple inhibitory receptors during chronic viral infection[J].Nat Immunol,2009,10(1):29-37.
|
|
[54]FISICARO P,VALDATTA C,MASSARI M,et al.Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B[J].Gastroenterology,2010,138(2):682-693.
|
|
[55]NEBBIA G,PEPPA D,SCHURICH A,et al.Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection[J].PLoS One,2012,7(10):e47648.
|
|
[56]SCHRICH A,KHANNA P,LOPES AR,et al.Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection[J].Hepatology,2011,53(5):1494-1503.
|
|
[57]PEPPA D,MICCO L,JAVAID A,et al.Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection[J].PLoS Pathog,2010,6(12):e1001227.
|
|
[58]SANGRO B,CROCENZI TS,WELLINGE TH,et al.Phase I dose escalation study of nivolumab(Anti-PD-1;BMS-936558;ONO-4538)in patients(pts)with advanced hepatocellular carcinoma(HCC)with or without chronic viral hepatitis[J].J Clin Oncol,2013,31(Suppl):abstr TPS3111.
|
|
[59]CHEN L.Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity[J].Nat Rev Immunol,2004,4(5):336-347.
|
|
[60]EBERT G,ALLISON C,PRESTON S,et al.Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J].Proc Natl Acad Sci U S A,2015,112(18):5803-5808.
|
|
[61]HO GY,BURK RD,KLEIN S,et al.Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia[J].J Natl Cancer Inst,1995,87(18):1365-1371.
|
|
[62]MOSKOPHIDIS D,LECHNER F,HENGARTNER H,et al.MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice[J].J Immunol,1994,152(10):4976-4983.
|
|
[63]OXENIUS A,ZINKERNAGEL RM,HENGARTNER H.Comparison of activation versus induction of unresponsiveness of virusspecific CD4+and CD8+T cells upon acute versus persistent viral infection[J].Immunity,1998,9(4):449-457.
|
|
[64]ZHANG E,KOSINSKA A,LU M,et al.Current status of immunomodulatory therapy in chronic hepatitis B,fifty years after discovery of the virus:search for the"magic bullet"to kill ccc DNA[J].Antiviral Res,2015,123(11):193-203.
|
|
[65]VANDEPAPELIERE P,LAU GK,LEROUX-ROELS G,et al.Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy:a randomized,control ed study of co-administration of HBs Ag/AS02 candidate vaccine and lamivudine[J].Vaccine,2007,25(51):8585-8597.
|
|
[66]GAGGAR A,COESHOTT C,APELIAN D,et al.Safety,tolerability and immunogenicity of GS-4774,a hepatitis B virus-specific therapeutic vaccine,in healthy subjects:a randomized study[J].Vaccine,2014,32(39):4925-4931.
|
|
[67]LOK AS,PAN CQ,HAN SH,et al.Safety and efficacy of GS-4774 in patients with chronic hepatitis B on oral antiviral therapy[J].Hepatology,2015,62:1181a.
|
|
[68]FONTAINE H,KAHI S,CHAZALLON C,et al.Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B:a randomised trial——ANRS HB02 VAC-ADN[J].Gut,2015,64(1):139-147.
|
DownLoad: